Shaping the future of drug development
Improving the design and implementation
of clinical trials
Powering your trial to success
Comprehensive software solutions for
designing and running your trials
SOFTWARE SOLUTIONS
Experience   Expertise   Innovation
Succeed in your clinical development with
our design and implementation advice
STRATEGIC CONSULTING
Getting it right the first time
Providing expertise and experience to
get you the best information from your trial
CLINICAL RESEARCH SERVICES

 SOFTWARE SOLUTIONS

Rigorously tested and continuously validated in practice, Cytel software is used at thousands of pharmaceutical, biotech, medical device companies, and leading independent research institutes.

 STRATEGIC CONSULTING

Cytel’s cutting-edge trial design and implementation expertise, with a specialty in adaptive trials, is helping sponsor companies of all sizes to increase success rates in clinical development.

 CLINICAL RESEARCH SERVICES

For proven product development knowledge and experience, rely on our global multi-disciplinary teams – biostatisticians, operations experts, data managers, programmers and medical writers.


Latest News & Events

DIA/Cytel Webinar Nov-20: Clinical Trials Reinvented - Register Free

Laurie Halloran and Cytel’s Irving Dark reveal the innovative product development advancements now helping clinical trial sponsors transform their trial strategies and practices.

CMO Summit West, San Francisco, November 3rd and 4th

Our workshop Nov 4th with Bay Area Onyx Pharmaceuticals for CMOs, CSOs, and fellow stakeholders on using adaptive designs and trial simulations to mitigate oncology development risk.

Cytel Remembers Friend and Board Member Marvin Zelen

So many labels applied to Marvin: scientist, educator, mentor, but perhaps they can be best summed as 'humanitarian'.

What Clients Say

Cytel’s work on the trial design, simulations and FDA discussions were instrumental in obtaining the regulatory acceptance for our proposed, ground-breaking methodology.

Implementation was smoother thanks to their experience with adaptive population enrichment strategies.

Simona Skerjanec, VP Medical Science
The Medicines Company

Cytel’s innovative, yet practical adaptive design provided multiple favorable scenarios allowing us stage the Phase 3 VALOR leukemia treatment trial based on sample size re-estimation.

Difficult to imagine our going forward with traditional clinical trial methods alone.

Steven B. Ketchum, VP Research and Development
Sunesis Pharmaceuticals

Working with Cytel allowed our team to move forward from research to reality swiftly.

We now have the tools to guide our innovative trial decision-making much more efficiently and knowledgably.

Joe Heyes, VP
Early Stage Biostatistics Merck

To my knowledge, Fulyzaq® is the very first approved treatment following a two-stage adaptive pivotal study.

There’s no question that without Cytel we wouldn’t have achieved that. You have been very service-oriented and responsive throughout.

Dr. Scott Harris, CMO
Napo Pharmaceuticals

We learned controlling critical operational variables with ongoing collaboration – especially between data managers and statisticians – was crucial to trial success.

We even saved 20% by outsourcing the key data analytics, medical writing and submission preparation functions with Cytel.

Dr. Patrice Rioux, VP, CMO
Raptor Pharmaceuticals

The Cytel team understood precisely what we needed, and delivered quality work within a very demanding timeframe.

They did it right the first time. As a result, we provided the FDA-requested safety reports without impacting our development timelines.

Sylvain Nicolas, Global Head Biostatistics Phase 1 Studies
Sanofi


Explore Our Products
Case Studies

Copyright © 2014 Cytel. All rights reserved